<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02892227</url>
  </required_header>
  <id_info>
    <org_study_id>AOI/2015/JER-01</org_study_id>
    <nct_id>NCT02892227</nct_id>
  </id_info>
  <brief_title>Management of Acute Heart Failure: Contribution of Ultrasound Daily &quot;in Bed Patient&quot; Adjustment on Therapy With Impact Measure on re Hospital Rate During 30 Days</brief_title>
  <acronym>JECICA</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <brief_summary>
    <textblock>
      Our hypothesis: a daily bedside echocardiographic assessment, protocolized, simple and&#xD;
      reproducible estimation of filling pressures with an evaluation of mitral inflow and the&#xD;
      inferior vena cava, allow a more reliable estimate of the true blood volume of the patient&#xD;
      and thus lead to a therapeutic adjustment more suitable.&#xD;
&#xD;
      This therapeutic adjustment closer to patient's needs would impact fewer readmissions at 30&#xD;
      days and mortality, less alteration of biological parameters myocardial, kidney and liver.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 15, 2016</start_date>
  <completion_date type="Actual">June 22, 2019</completion_date>
  <primary_completion_date type="Actual">January 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>rehospitalization</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>worsening heart failure</measure>
    <time_frame>during hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average length of stay</measure>
    <time_frame>during hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>alteration of biological parameters myocardial, kidney and liver</measure>
    <time_frame>Hospital discharge +7 days, Hospital discharge +30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>JET ECHO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transmitral flow estimation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NO JET ECHO</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no bedside echocardiography</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transmitral flow estimation</intervention_name>
    <description>Estimation of the transmitral flow of the inferior vena cava and its variations</description>
    <arm_group_label>JET ECHO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The patient or his representative must be given free and informed consent and signed&#xD;
        consent.&#xD;
&#xD;
          -  The patient must be affiliated or beneficiary of a health insurance plan.&#xD;
&#xD;
          -  The patient is available for a follow-up 6 months.&#xD;
&#xD;
          -  The patient is of age or older (&gt;) 18.&#xD;
&#xD;
          -  Patients hospitalized for acute heart failure who received at least 40mg of furosemide&#xD;
             IV.&#xD;
&#xD;
          -  Patient with impaired LVEF &lt;50%.&#xD;
&#xD;
          -  Patient with Nt-proBNP values&gt; 1200pg / ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject takes part in another study.&#xD;
&#xD;
               -  The subject is exclusion period determined by a previous study.&#xD;
&#xD;
               -  The subject is under judicial protection.&#xD;
&#xD;
               -  The subject or his representative refuses to sign the consent.&#xD;
&#xD;
               -  It is not possible to give the subject or his representative informed&#xD;
                  information.&#xD;
&#xD;
        Non-inclusion criteria for those diseases or conditions associated (s) interfere (s):&#xD;
&#xD;
          -  The patient is pregnant or is breastfeeding.&#xD;
&#xD;
          -  The patient is already included in a surveillance program (PRADO, OSICAT).&#xD;
&#xD;
          -  Patient with a mechanical or biological mitral prosthesis.&#xD;
&#xD;
          -  History of mitral stenosis.&#xD;
&#xD;
          -  severe valvular surgery with maturity in months (&lt;30 days).&#xD;
&#xD;
          -  chronic renal impairment on dialysis.&#xD;
&#xD;
          -  High grade AV block (AVB and BAV3 2/1).&#xD;
&#xD;
          -  Hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  Cardiogenic shock.&#xD;
&#xD;
          -  Contraindications to furosemide.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bedside echography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

